3 Biotechs Facing FDA Approvals by Year's End

Biotech investors know that simply generating some positive clinical trial data for a candidate treatment is no guarantee that the drug will make it to market. The U.S. Food and Drug Administration (FDA) looks deep before giving its approval. And when a company announces that it has received either an FDA approval letter -- or its dreaded counterpart, the complete response letter -- that can dramatically impact its stock price.